Zou, Jianxuan
Jones, Richard J.
Wang, Hua
Kuiatse, Isere
Shirazi, Fazal
Manasanch, Elisabet E.
Lee, Hans C.
Sullivan, Robert
Fung, Leah
Richard, Normand
Erdman, Paul
Torres, Eduardo
Hecht, David
Lam, Imelda
McElwee, Brooke
Chourasia, Aparajita H.
Chan, Kyle W. H.
Mercurio, Frank
Stirling, David I.
Orlowski, Robert Z. http://orcid.org/0000-0002-5723-4129
Funding for this research was provided by:
BioTheryX
National Cancer Institute (R01s CA184464 and CA194264)
Leukemia & Lymphoma Society Specialized Center of Research (SCOR-12206-17)
Dr. Mirian and Sheldon G. Adelson Research Foundation
Article History
Received: 2 April 2020
Revised: 31 May 2020
Accepted: 18 June 2020
First Online: 6 July 2020
Compliance with ethical standards
:
: RS, LF, NR, PE, ET, IL, BM, AHC, KWHC, FM, and DIS are employees of BioTheryX, Inc., while the other authors have no financial conflicts of interest to declare with respect to BioTheryX, Inc.EEM has received research support from Sanofi, Quest Diagnostics, Novartis, JW Pharma, and Merck, and consultant fees from Takeda, Celgene, Sanofi, Janssen, GSK, and Adaptive Biotechnologies. HCL has provided consultancy services to Amgen, Inc., Celgene, a wholly owned subsidiary of Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutical, Sanofi-Aventis, and Takeda Pharmaceutical, and has received research funding from Amgen, Inc., Celgene, a wholly owned subsidiary of Bristol-Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Janssen Pharmaceutical, and Takeda Pharmaceuticals. RZO declares laboratory research funding from BioTheryX, and clinical research funding from CARsgen Therapeutics, Celgene, Exelixis, Janssen Biotech, Sanofi-Aventis, Takeda Pharmaceuticals North America, Inc. Also, RZO has served on advisory boards for Amgen, Inc., Bristol-Myers Squibb, Celgene, EcoR1 Capital LLC, Forma Therapeutics, Genzyme, GSK Biologicals, Ionis Pharmaceuticals, Inc., Janssen Biotech, Juno Therapeutics, Kite Pharma, Legend Biotech USA, Molecular Partners, Regeneron Pharmaceuticals, Inc., Sanofi-Aventis, Servier, and Takeda Pharmaceuticals North America, Inc., and is a Founder of Asylia Therapeutics, Inc., with associated patents and an equity interest, though this technology does not bear on the current manuscript.